CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity

Core Insights - CytoDyn Inc. is advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, with potential applications in multiple cancer types, including triple-negative breast cancer (TNBC) and colorectal cancer (CRC) [1][3] - The company will present findings on leronlimab's effects on PD-L1 expression and patient survival in metastatic TNBC at the AACR Special Conference in Cancer Research [1][3] - A retrospective analysis indicated that leronlimab treatment led to PD-L1 expression in 88% of patients treated with doses greater than 525 mg/week, suggesting improved survival outcomes when combined with immune checkpoint inhibitors (ICIs) [1][4] Presentation Details - The oral and poster presentations will take place on September 26 and 27, 2025, respectively, focusing on the association between CCR5 inhibition, enhanced PD-L1 expression, and long-term survival in metastatic TNBC [3][4] Clinical Implications - The findings suggest that leronlimab may enhance the effectiveness of ICIs in patients with metastatic TNBC, a group historically resistant to such treatments [2][4] - The study showed that 18% of heavily pretreated metastatic TNBC patients were alive after a median of approximately 60 months, indicating a potential survival benefit from CCR5 inhibition [4] Company Overview - CytoDyn is dedicated to developing leronlimab as a versatile therapeutic platform aimed at addressing serious unmet medical needs across various high-value markets [5] - The company emphasizes its commitment to improving patients' quality of life through innovative therapies [5]